- Home
- CWCO vs MREO Comparison
CWCO vs MREO Comparison
Compare CWCO & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWCO
- MREO
- Stock Information
- Founded
- CWCO 1973
- MREO 2015
- Country
- CWCO Cayman Islands
- MREO United Kingdom
- Employees
- CWCO N/A
- MREO N/A
- Industry
- CWCO Water Supply
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- CWCO Utilities
- MREO Health Care
- Exchange
- CWCO Nasdaq
- MREO Nasdaq
- Market Cap
- CWCO 402.4M
- MREO 369.2M
- IPO Year
- CWCO N/A
- MREO N/A
- Fundamental
- Price
- CWCO $24.38
- MREO $2.37
- Analyst Decision
- CWCO
- MREO Strong Buy
- Analyst Count
- CWCO 0
- MREO 7
- Target Price
- CWCO N/A
- MREO $7.71
- AVG Volume (30 Days)
- CWCO 195.4K
- MREO 1.2M
- Earning Date
- CWCO 03-17-2025
- MREO 03-26-2025
- Dividend Yield
- CWCO 1.80%
- MREO N/A
- EPS Growth
- CWCO N/A
- MREO N/A
- EPS
- CWCO 1.77
- MREO N/A
- Revenue
- CWCO $133,966,633.00
- MREO N/A
- Revenue This Year
- CWCO N/A
- MREO N/A
- Revenue Next Year
- CWCO $62.30
- MREO $69.09
- P/E Ratio
- CWCO $13.79
- MREO N/A
- Revenue Growth
- CWCO N/A
- MREO N/A
- 52 Week Low
- CWCO $23.55
- MREO $2.11
- 52 Week High
- CWCO $30.32
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- CWCO 35.22
- MREO 43.95
- Support Level
- CWCO $24.05
- MREO $2.23
- Resistance Level
- CWCO $24.92
- MREO $2.73
- Average True Range (ATR)
- CWCO 0.91
- MREO 0.16
- MACD
- CWCO -0.30
- MREO -0.00
- Stochastic Oscillator
- CWCO 14.41
- MREO 41.94
About CWCO Consolidated Water Co. Ltd.
Consolidated Water Co Ltd is a water utility company. It develops and operates seawater desalination plants and water distribution systems. The company's business segments are; The retail segment operates the water utility for the Seven Mile Beach and West Bay areas of Grand Cayman Island, The bulk segment supplies potable water to government utilities in Grand Cayman and The Bahamas under long-term contracts, The services segment designs, constructs and sells water infrastructure and provides management and operating services to third parties, and The manufacturing segment manufactures and services a wide range of custom and specialized water-related products applicable to commercial, municipal and industrial water production, supply and treatment.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).